Send me real-time posts from this site at my email

Watchlist Update Sept 12 : HZNP - Horizon Pharma - Analyst Comments

TIGER'S TAKE:   On our trading list. A good longer term biotech/drug stock. Due to its volatility, options trading around a position can be profitable.   $HZNP

Horizon Pharma initiated with a Buy at Guggenheim

Guggenheim analyst Dana Flanders initiated Horizon Pharma with a Buy rating and a $36 price target, calling the company his "Best Idea." The analyst has high confidence in the growth potential of Horizon's drugs Krystexxa and teprotumumab, and believes they will drive upside to margins over the next 3-5 years. Flanders also expects a "strong" tepro launch in Q1 of 2020.

Source: (

$HZNP, Horizon Therapeutics Public Limited Company / H1

Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.

If you liked this article, please click the LIKE (thumbs up) button.

Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so).

Follow us/bookmark us and check back occasionally for additional articles or comments on our page...

Wild Tiger Trading - start/main page.

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue